As of September 30, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $521.9 million, providing runway for announced indications through GD readout expected in 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT: